Brodalumab Application Under Review for Plaque Psoriasis

Article

The FDA is examining a biologics license application for brodalumab injection 210 mg as a treatment for moderate to severe plaque psoriasis.

The FDA is examining a biologics license application for brodalumab injection 210 mg as a treatment for moderate to severe plaque psoriasis.

The application for the monoclonal antibody that targets the IL-17 receptor was submitted on behalf of AstraZeneca and Valeant Pharmaceuticals.

The FDA has scheduled an action date for November 16, 2016.

The application submitted to the FDA includes data from 3 phase 3 studies, which showed that brodalumab was effective at helping patients achieve total clearance of the disease.

In 2 trials involving more than 3500 patients, patients receiving a 210 mg dose of brodalumab saw greater skin clearance than the placebo group at week 12. Brodalumab was also shown to be superior to ustekinumab.

The most common adverse effects associated with the drug are headache, arthralgia, fatigue, oropharyngeal pain, and diarrhea.

Patients with Crohn’s disease should be cautious about the use of brodalumab.

Related Videos
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Image credit: rawpixel.com | stock.adobe.com
Medical team -- Image credit: Flamingo Images | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.